Abstract
Treatment with statins represents an essential component both of primary and secondary cardiovascular prevention strategies. However, a proportion of patients cannot reach low-density lipoprotein cholesterol (LDL-C) targets with the highest tolerable dose of a potent statin or is intolerant to statins. Several treatment options are available for these patients. Colesevelam is a relatively new bile acid sequestrant that decreases serum LDL-C levels. Moreover, colesevelam improves glycemic control and seems to be well-tolerated, at least in short-term studies. Therefore, colesevelam seems to be a useful tool for the management of high-risk patients who cannot achieve LDL-C targets with monotherapy with a potent statin.
Keywords: Colesevelam, statin intolerance, glycemic control, multifactorial intervention, type 2 diabetes mellitus.
Current Pharmaceutical Design
Title:Colesevelam: A New and Improved Bile Acid Sequestrant?
Volume: 19 Issue: 17
Author(s): Konstantinos Tziomalos, Asterios Karagiannis, Dimitri P. Mikhailidis and Vasilios G. Athyros
Affiliation:
Keywords: Colesevelam, statin intolerance, glycemic control, multifactorial intervention, type 2 diabetes mellitus.
Abstract: Treatment with statins represents an essential component both of primary and secondary cardiovascular prevention strategies. However, a proportion of patients cannot reach low-density lipoprotein cholesterol (LDL-C) targets with the highest tolerable dose of a potent statin or is intolerant to statins. Several treatment options are available for these patients. Colesevelam is a relatively new bile acid sequestrant that decreases serum LDL-C levels. Moreover, colesevelam improves glycemic control and seems to be well-tolerated, at least in short-term studies. Therefore, colesevelam seems to be a useful tool for the management of high-risk patients who cannot achieve LDL-C targets with monotherapy with a potent statin.
Export Options
About this article
Cite this article as:
Tziomalos Konstantinos, Karagiannis Asterios, Mikhailidis Dimitri P. and Athyros Vasilios G., Colesevelam: A New and Improved Bile Acid Sequestrant?, Current Pharmaceutical Design 2013; 19 (17) . https://dx.doi.org/10.2174/1381612811319170019
DOI https://dx.doi.org/10.2174/1381612811319170019 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidation Chemistry of Catecholamines and Neuronal Degeneration: An Update
Current Medicinal Chemistry Preliminary Screening Indicates Promising Antimicrobial Properties of the Stem Bark Extracts of Macaranga rosea
Anti-Infective Agents The Evidence Base for Revascularisation of Chronic Total Occlusions
Current Cardiology Reviews Mechanisms of Esophageal Protection, Gastroprotection and Ulcer Healing by Melatonin. Implications for the Therapeutic use of Melatonin in Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease
Current Pharmaceutical Design Current and Future Therapeutic Strategies in NAFLD
Current Pharmaceutical Design Is Adrenaline Always the First Choice Therapy of Anaphylaxis? An Allergist-cardiologist Interdisciplinary Point of View
Current Pharmaceutical Design Apoptosis: A Potential Therapeutic Target for Retinal Degenerations
Current Neurovascular Research Patenting of Nanopharmaceuticals in Drug Delivery: No Small Issue
Recent Patents on Drug Delivery & Formulation Sleep Apnea and Coronary Heart Disease: From Dusk Till Dawn and Further
Current Respiratory Medicine Reviews Evidence-Based Percutaneous Closure of the Left Atrial Appendage in Patients with Atrial Fibrillation
Current Cardiology Reviews Cardiovascular Risk Factors and Dietary Patterns
Current Nutrition & Food Science The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction
Current Pharmaceutical Design Risk Factors for Heart Failure Progression and Outcomes
Current Cardiology Reviews Adiposity and Alzheimers Disease
Current Alzheimer Research A Review of Evolutionary and Cyclical Changes in the Surgical Approach to Aortic Valve Disease
Reviews on Recent Clinical Trials Atorvastatin-Loaded Oleic Acid Nanoglobules for Oral Administration: In Vitro Characterization and Biopharmaceutical Evaluation
Current Nanoscience Diltiazem Analogues: The Last Ten Years on Structure Activity Relationships
Current Medicinal Chemistry Omentin: Linking Metabolic Syndrome and Cardiovascular Disease
Current Vascular Pharmacology Clinical Use of Neurophysiological Biomarkers and Self-Assessment Scales to Predict and Monitor Treatment Response for Psychotic and Affective Disorders
Current Pharmaceutical Design Aldose Reductase in Diabetic Microvascular Complications
Current Drug Targets